Company Description
Prenetics Global Limited, a genomics-driven health sciences company, engages in prevention, early detection, and treatment.
It operates through two segments: Prevention and Diagnostics. Its prevention arm, CircleDNA, uses whole exome sequencing to offer comprehensive consumer DNA test.
It also develops and commercializes Insighta, a multi-cancer early detection technology. In addition, the company offers a range of genomic profiling panels tailored for requirements and clinician needs, including ACTOnco, ACT HRD, ACTFusion, and ACTDrug tests.
Further, the company offers ACTLiquid Pro, a sequencing based liquid biopsy assay for pan-solid tumors; ACTMonitor, which provides real time monitoring of drug resistance, treatment response, and cancer recurrence; and ACT Risk, which manages the cancer risk.
It operates in Taiwan, Hong Kong, the United Kingdom, and internationally. Prenetics Global Limited is based in Quarry Bay, Hong Kong.
Country | Hong Kong |
Founded | 2014 |
Industry | Diagnostics & Research |
Sector | Healthcare |
Employees | 320 |
CEO | Sheng Wu Yeung |
Contact Details
Address: 7/f, K11 Atelier, 728 King's Road Quarry Bay, K3 000000 Hong Kong | |
Phone | (852) 2210-7188 |
Website | prenetics.com |
Stock Details
Ticker Symbol | PRE |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001876431 |
CUSIP Number | G72245106 |
ISIN Number | KYG722451229 |
SIC Code | 3826 |
Key Executives
Name | Position |
---|---|
Walt Ling | Chief Executive Officer of ACT Genomics |
Joel Neoh | Chief Consumer Officer and Chief Executive Officer for CircleDNA |
Samantha Kwok | Chief of Staff to Group Chief Executive Officer and Vice President, People & Operations |
Sheng Wu Yeung | Co-Founder, Chairperson and Chief Executive Officer |
Dr. Chi Hung Tzang Ph.D. | Co-Founder, Chief Scientific Officer and Member of Scientific Advisory Board |
Hoi Chun Lo | Chief Financial Officer |
Dr. Yung Ho Wong DPHIL | Chief Technology Officer |
Dr. Senthil Sundaram M.D. | Chief Clinical Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Jun 18, 2024 | 6-K | Report of foreign issuer |
May 21, 2024 | 6-K | Report of foreign issuer |
May 1, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
May 1, 2024 | 20-F | Annual and transition report of foreign private issuers |
Apr 1, 2024 | 6-K | Report of foreign issuer |
Feb 16, 2024 | EFFECT | Notice of Effectiveness |
Feb 16, 2024 | 424B3 | Prospectus |
Feb 5, 2024 | F-3/A | Filing |
Feb 5, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Jan 26, 2024 | UPLOAD | Filing |